Tag: Psoriasis
AAD: Ustekinumab Cuts Vascular Inflammation in Psoriasis
Reduction in total aortic vascular inflammation with ustekinumab versus increase with placebo
Patient-Initiated Consultations Beneficial in Psoriasis
No difference seen in Dermatology Life Quality Index versus routine care but fewer consultation requests
Psoriasis Remission Described After Hepatitis C Virus Treatment
Case report: After initiation of ledipasvir-sofosbuvir, HCV RNA decreased, and skin lesions improved
Psoriasis Is Independent Risk Factor for Comorbidity in Children
Those with psoriasis at higher risk for diabetes, liver disease, elevated lipid levels independent of obesity
The American College of Rheumatology, Nov. 3-8
The 81st Annual Meeting of the American College of Rheumatology The annual meeting of the American College of Rheumatology was held...
Tofacitinib Superior to Placebo in Active Psoriatic Arthritis
Tofacitinib is superior for patients with inadequate response to TNF inhibitors or conventional DMARDs
Secukinumab Effective for Moderate/Severe Scalp Psoriasis
Over half of patients have 90 percent improvement on Psoriasis Scalp Severity Index score
Noninvasive Test for NASH, Fibrosis in Patients With Psoriasis
Correlation for cumulative methotrexate dose with higher score on NASH FibroSure in women
ABP 501, Adalimumab Biosimilar, Safe and Effective, for Psoriasis
Findings based on comparison over 52 weeks, including single transition
Tofacitinib Associated With Improvement in Nail Psoriasis
Improvement in nail psoriasis severity at 16 weeks versus placebo; maintained through 52 weeks
